[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1111171T1 - Ανυδρες κρυσταλλικες μορφες ν-[1-(2-αιθοξυαιθυλ)-5-(ν-αιθυλ-ν-μεθυλαμινο)-7-(4-μεθυλπυριδιν-2-υλ-αμινο)-1η-πυραζολο [4,3-d]πυριμιδινο-3-καρβονυλ]μεθανοσουλφοναμιδιου - Google Patents

Ανυδρες κρυσταλλικες μορφες ν-[1-(2-αιθοξυαιθυλ)-5-(ν-αιθυλ-ν-μεθυλαμινο)-7-(4-μεθυλπυριδιν-2-υλ-αμινο)-1η-πυραζολο [4,3-d]πυριμιδινο-3-καρβονυλ]μεθανοσουλφοναμιδιου

Info

Publication number
CY1111171T1
CY1111171T1 CY20111100142T CY111100142T CY1111171T1 CY 1111171 T1 CY1111171 T1 CY 1111171T1 CY 20111100142 T CY20111100142 T CY 20111100142T CY 111100142 T CY111100142 T CY 111100142T CY 1111171 T1 CY1111171 T1 CY 1111171T1
Authority
CY
Cyprus
Prior art keywords
methanesulfonamide
methylpyridin
ethoxyethyl
methylamino
carbonyl
Prior art date
Application number
CY20111100142T
Other languages
English (en)
Inventor
David Andrew Entwistle
Peter Vallance Marshall
Stefan Colin John Taylor
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1111171T1 publication Critical patent/CY1111171T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)

Abstract

Η εφεύρεση περιλαμβάνει (1) άνυδρες κρυσταλλικές μορφές του Ν-[1-(2-αιθοξυαιθυλ)-5-(Ν-αιθυλ-Ν-μεθυλαμινο)-7-(4-μεθυλ-πυριδιν-2-υλ-αμινο)-1Η-πυραζολο[4,3-d]πυριμιδινο-3-καρβονυλ]-μεθανοσουλφοναμιδιου, (2) φαρμακευτικές συνθέσεις που περιλαμβάνουν τουλάχιστον μια τέτοια μορφή, (3) μεθόδους για τη θεραπεία προκαλούμενης από φωσφοδιεστεράση-5 κατάστασης χρησιμοποιώντας τουλάχιστον μία τέτοια μορφή και (4) μεθόδους παρασκευής τέτοιων μορφών.
CY20111100142T 2005-05-12 2011-02-08 Ανυδρες κρυσταλλικες μορφες ν-[1-(2-αιθοξυαιθυλ)-5-(ν-αιθυλ-ν-μεθυλαμινο)-7-(4-μεθυλπυριδιν-2-υλ-αμινο)-1η-πυραζολο [4,3-d]πυριμιδινο-3-καρβονυλ]μεθανοσουλφοναμιδιου CY1111171T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68044505P 2005-05-12 2005-05-12
US68171105P 2005-05-17 2005-05-17
EP06744689A EP1881985B1 (en) 2005-05-12 2006-05-03 Anhydrous crystalline forms of n-ý1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl¨methanesulfonamide

Publications (1)

Publication Number Publication Date
CY1111171T1 true CY1111171T1 (el) 2015-06-11

Family

ID=37106941

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100142T CY1111171T1 (el) 2005-05-12 2011-02-08 Ανυδρες κρυσταλλικες μορφες ν-[1-(2-αιθοξυαιθυλ)-5-(ν-αιθυλ-ν-μεθυλαμινο)-7-(4-μεθυλπυριδιν-2-υλ-αμινο)-1η-πυραζολο [4,3-d]πυριμιδινο-3-καρβονυλ]μεθανοσουλφοναμιδιου

Country Status (24)

Country Link
US (3) US8227475B2 (el)
EP (1) EP1881985B1 (el)
JP (2) JP4271695B2 (el)
KR (1) KR100939890B1 (el)
AT (1) ATE493413T1 (el)
AU (1) AU2006245416B2 (el)
BR (1) BRPI0609225A2 (el)
CA (1) CA2608018C (el)
CR (1) CR9505A (el)
CY (1) CY1111171T1 (el)
DE (1) DE602006019231D1 (el)
DK (1) DK1881985T3 (el)
EA (1) EA012577B1 (el)
HK (1) HK1116485A1 (el)
IL (1) IL186693A (el)
MA (1) MA29447B1 (el)
MX (1) MX2007013215A (el)
NO (1) NO20075258L (el)
NZ (1) NZ564187A (el)
PL (1) PL1881985T3 (el)
PT (1) PT1881985E (el)
TN (1) TNSN07414A1 (el)
TW (1) TWI380986B (el)
WO (1) WO2006120552A2 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7676953B2 (en) 2006-12-29 2010-03-16 Signature Control Systems, Inc. Calibration and metering methods for wood kiln moisture measurement
WO2009050554A2 (en) * 2007-10-19 2009-04-23 Pfizer Inc. Treatment of central nervous system disorders
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
SG194549A1 (en) 2011-04-21 2013-12-30 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
CA2888160A1 (en) 2012-10-23 2014-05-01 Pfizer Inc. Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy
JP2016502978A (ja) 2012-12-11 2016-02-01 ファイザー・インク ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014097038A1 (en) 2012-12-19 2014-06-26 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MX2015010714A (es) 2013-02-19 2016-06-14 Pfizer Compuestos de azabencimidazol.
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
CR20160454A (es) 2014-04-01 2016-12-06 Pfizer CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
PE20170327A1 (es) 2014-04-10 2017-04-21 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
EA033423B1 (ru) 2015-02-03 2019-10-31 Pfizer Циклопропанбензофуранилпиридопиразиндионы
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
US10323042B2 (en) 2016-02-23 2019-06-18 Pfizer Inc. 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
ES2878160T3 (es) 2016-07-01 2021-11-18 Pfizer Derivados de 5,7-dihidro-pirrolo-piridina para el tratamiento de enfermedades neurológicas y neurodegenerativas
PT3642202T (pt) 2017-06-22 2023-02-02 Pfizer Derivados de dihidro-pirrolo-piridina
FI3768669T3 (fi) 2018-03-23 2023-04-26 Pfizer Piperatsiiniatsaspirojohdannaisia
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
EA004315B1 (ru) 1997-04-25 2004-02-26 Пфайзер Инк. Новые сульфонилбензойные кислоты и способ получения 4-бензамидопиразоло-5-карбоксамидов с их использованием
ATE213246T1 (de) 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
HUP0102543A3 (en) 1998-04-20 2002-01-28 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
WO2000024745A1 (en) 1998-10-23 2000-05-04 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
DE19942474A1 (de) 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
TR200200954T2 (tr) 1999-10-11 2002-09-23 Pfizer Inc. Fosfodiesteraz inhibitörleri olarak 5-(2-ikame edilmiş-5-heterosiklilsülfonilpirid-3-il)- dihidropirazolo[4,3- D]pirimidin-7-onlar.
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
DE10031584A1 (de) 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
HUP0302982A3 (en) 2000-07-28 2005-01-28 Pfizer Crystalline therapeutic agent
DK1348707T3 (da) * 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
RS20050810A (en) 2003-04-29 2007-08-03 Pfizer Inc., 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
GB0327323D0 (en) 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1742950B1 (en) 2004-04-07 2008-12-17 Pfizer Limited Pyrazolo[4,3-d] pyrimidines
EP1809632A2 (en) 2004-10-28 2007-07-25 Pharmacia & Upjohn Company LLC Pyrazolo[4,3-d]pyrimidine derivatives useful as pde-5 inhibitors

Also Published As

Publication number Publication date
US8796288B2 (en) 2014-08-05
CA2608018A1 (en) 2006-11-16
JP4996631B2 (ja) 2012-08-08
TNSN07414A1 (fr) 2009-03-17
US20120208830A1 (en) 2012-08-16
MA29447B1 (fr) 2008-05-02
CR9505A (es) 2008-01-02
KR100939890B1 (ko) 2010-01-29
NO20075258L (no) 2007-11-15
JP4271695B2 (ja) 2009-06-03
JP2009137987A (ja) 2009-06-25
MX2007013215A (es) 2007-12-12
EA200702217A1 (ru) 2008-04-28
NZ564187A (en) 2010-03-26
WO2006120552A2 (en) 2006-11-16
ATE493413T1 (de) 2011-01-15
TW200716641A (en) 2007-05-01
PL1881985T3 (pl) 2011-05-31
BRPI0609225A2 (pt) 2010-03-09
EA012577B1 (ru) 2009-10-30
PT1881985E (pt) 2011-02-01
US8796287B2 (en) 2014-08-05
IL186693A (en) 2012-07-31
TWI380986B (zh) 2013-01-01
IL186693A0 (en) 2008-02-09
AU2006245416A1 (en) 2006-11-16
DE602006019231D1 (en) 2011-02-10
US20120214827A1 (en) 2012-08-23
AU2006245416B2 (en) 2012-02-23
WO2006120552A3 (en) 2007-01-18
US8227475B2 (en) 2012-07-24
DK1881985T3 (da) 2011-02-14
EP1881985B1 (en) 2010-12-29
CA2608018C (en) 2010-07-13
KR20080004593A (ko) 2008-01-09
JP2006316058A (ja) 2006-11-24
HK1116485A1 (el) 2008-12-24
US20080194591A1 (en) 2008-08-14
EP1881985A2 (en) 2008-01-30

Similar Documents

Publication Publication Date Title
CY1111171T1 (el) Ανυδρες κρυσταλλικες μορφες ν-[1-(2-αιθοξυαιθυλ)-5-(ν-αιθυλ-ν-μεθυλαμινο)-7-(4-μεθυλπυριδιν-2-υλ-αμινο)-1η-πυραζολο [4,3-d]πυριμιδινο-3-καρβονυλ]μεθανοσουλφοναμιδιου
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
CY1117639T1 (el) Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
SE0301372D0 (sv) Novel compounds
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2007002635A3 (en) C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
WO2009043889A3 (en) Oxadiazole derivatives
GT200600148A (es) Metodos para el tratamiento y la prevencion de fibrosis
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
NO20090596L (no) Antivirale fosfinatforbindelser
EA200801199A1 (ru) Ингибиторы киназы
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
NO20081160L (no) Benzimidazoltiofen forbindelser
WO2007120333A3 (en) Tetracyclic kinase inhibitors
TW200731974A (en) Transdermal system for verenicline
WO2007070562A3 (en) Non-hygroscopic compositions of enterostatin
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
WO2007070563A3 (en) Stable solid forms of enterostatin